PMID- 20377113
OWN - NLM
STAT- MEDLINE
DCOM- 20100610
LR  - 20240109
IS  - 1081-1206 (Print)
IS  - 1534-4436 (Electronic)
IS  - 1081-1206 (Linking)
VI  - 104
IP  - 3
DP  - 2010 Mar
TI  - The traditional Chinese herbal formula ASHMI inhibits allergic lung inflammation 
      in antigen-sensitized and antigen-challenged aged mice.
PG  - 236-46
LID - 10.1016/j.anai.2009.12.006 [doi]
AB  - BACKGROUND: Although asthma is typically characterized as a childhood disease, it 
      can develop later in life. Older asthmatic patients may be at increased risk for 
      corticosteroid adverse effects. We developed a novel traditional Chinese medicine 
      to treat asthma called antiasthma simplified herbal medicine intervention 
      (ASHMI). Herbal products may offer safer adjunctive treatment for older asthmatic 
      patients. OBJECTIVE: To investigate the effects of ASHMI on characteristics of 
      allergic asthma in an aged mouse model of asthma. METHODS: BALB/c mice (6 weeks 
      old [young] and 6, 12, and 18 months old [aged]) received ASHMI treatment before 
      and during intraperitoneal ovalbumin sensitization and intratracheal challenges. 
      The control groups were untreated, age-matched, ovalbumin-sensitized and 
      ovalbumin-challenged mice (ovalbumin mice) and naive mice. After the final 
      antigen challenge, airway pressure (defined as the time-integrated change in peak 
      airway pressure) after acetylcholine provocation was measured, representing 
      airway hyperresponsiveness, and bronchoalveolar lavage fluid, sera, lung tissues 
      for histologic analysis, messenger RNA, and collagen were collected. RESULTS: 
      Mean time-integrated change in peak airway pressure values in 6-week-old and 6-, 
      12-, and 18-month-old ASHMI ovalbumin mice were significantly reduced compared 
      with those of age-matched, nontreated ovalbumin mice. Bronchoalveolar lavage 
      fluid eosinophil numbers were significantly lower in all ASHMI ovalbumin mice. 
      Treatment with ASHMI of young and aged ovalbumin mice resulted in significantly 
      decreased lung inflammation, detected via hematoxylin-eosin staining; airway 
      mucous cell metaplasia, determined by means of periodic acid-Schiff staining; and 
      messenger RNA copy numbers of the mucin gene MUC5AC. Levels of ovalbumin specific 
      IgE and the T(H)2 cytokines interleukin 4 (IL-4), IL-5, and IL-13 in lung and 
      splenocyte cultures were reduced. Interferon gamma secretion was increased. 
      Treatment with ASHMI reduced collagen production. CONCLUSION: Treatment with 
      ASHMI reduces several features of asthma in aged antigen-sensitized and 
      antigen-challenged mice.
FAU - Busse, Paula J
AU  - Busse PJ
AD  - Division of Clinical Immunology, Department of Medicine, Mount Sinai School of 
      Medicine, New York, New York 10029, USA. paula.busse@mssm.edu
FAU - Schofield, Brian
AU  - Schofield B
FAU - Birmingham, Neil
AU  - Birmingham N
FAU - Yang, Nan
AU  - Yang N
FAU - Wen, Ming-Chuan
AU  - Wen MC
FAU - Zhang, Tengfei
AU  - Zhang T
FAU - Srivastava, Kamal
AU  - Srivastava K
FAU - Li, Xiu-Min
AU  - Li XM
LA  - eng
GR  - K08 AI063932/AI/NIAID NIH HHS/United States
GR  - K08 AI063932-01A2/AI/NIAID NIH HHS/United States
GR  - P01 AT002647/AT/NCCIH NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Ann Allergy Asthma Immunol
JT  - Annals of allergy, asthma & immunology : official publication of the American 
      College of Allergy, Asthma, & Immunology
JID - 9503580
RN  - 0 (Anti-Asthmatic Agents)
RN  - 0 (Antigens)
RN  - 0 (Drugs, Chinese Herbal)
RN  - 9006-59-1 (Ovalbumin)
SB  - IM
MH  - Aging/immunology
MH  - Animals
MH  - Anti-Asthmatic Agents/*therapeutic use
MH  - Antigens/immunology
MH  - Asthma/*drug therapy/immunology
MH  - Drug Evaluation, Preclinical
MH  - Drugs, Chinese Herbal/*therapeutic use
MH  - Female
MH  - Mice
MH  - Mice, Inbred AKR
MH  - Mice, Inbred BALB C
MH  - Ovalbumin/immunology
MH  - Treatment Outcome
PMC - PMC4608683
MID - NIHMS245951
EDAT- 2010/04/10 06:00
MHDA- 2010/06/11 06:00
PMCR- 2015/10/16
CRDT- 2010/04/10 06:00
PHST- 2010/04/10 06:00 [entrez]
PHST- 2010/04/10 06:00 [pubmed]
PHST- 2010/06/11 06:00 [medline]
PHST- 2015/10/16 00:00 [pmc-release]
AID - S1081-1206(09)00120-3 [pii]
AID - 10.1016/j.anai.2009.12.006 [doi]
PST - ppublish
SO  - Ann Allergy Asthma Immunol. 2010 Mar;104(3):236-46. doi: 
      10.1016/j.anai.2009.12.006.